<div id="readability-page-1"><p>Brown Advisory Inc. lessened its stake in  LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 10.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 5,210,638 shares of the company's stock after selling 611,977 shares during the period. Brown Advisory Inc. owned approximately 1.34% of LifeStance Health Group worth $26,939,000 at the end of the most recent reporting period.</p><p>A number of other institutional investors have also recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. bought a new position in  LifeStance Health Group in the first quarter valued at $7,932,000.  Adage Capital Partners GP L.L.C. increased its position in shares of  LifeStance Health Group by 43.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 230,000 shares of the company's stock valued at $1,532,000 after purchasing an additional 70,000 shares during the last quarter.  TD Asset Management Inc purchased a new position in shares of  LifeStance Health Group during the 2nd quarter valued at about $780,000.  Nuveen LLC bought a new stake in  LifeStance Health Group in the 1st quarter worth approximately $6,928,000.  Finally, Los Angeles Capital Management LLC purchased a new stake in  LifeStance Health Group in the second quarter worth approximately $219,000. Institutional investors own  85.50% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of research analysts have commented on LFST shares. Zacks Research cut shares of LifeStance Health Group from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, November 5th. BMO Capital Markets began coverage on shares of LifeStance Health Group in a research report on Thursday, November 13th. They issued an &#34;outperform&#34; rating and a $8.00 target price on the stock. BTIG Research boosted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 6th. Wall Street Zen cut LifeStance Health Group from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, October 11th. Finally, UBS Group boosted their target price on LifeStance Health Group from $9.00 to $10.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, November 7th. One equities research analyst  has rated the stock with a Strong Buy rating, six have issued  a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $9.00.</p><p><b>Check Out Our Latest Stock Analysis on LFST</b></p><h2>Insider Buying and Selling at LifeStance Health Group</h2><p>In other news, insider Lisa K. Miller sold 57,240 shares of the business's stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $6.43, for a total transaction of $368,053.20. Following the transaction, the insider directly owned 261,292 shares of the company's stock, valued at approximately $1,680,107.56. The trade was a 17.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Corporate insiders own  3.20% of the company's stock. </p><h2>LifeStance Health Group Price Performance</h2><p>LFST stock opened at $6.48 on Friday. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -216.00 and a beta of 1.13. The firm's 50-day moving average price is $5.72 and its two-hundred day moving average price is $5.30. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18. LifeStance Health Group, Inc. has a 12-month low of $3.74 and a 12-month high of $8.30. </p><p>LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company had revenue of $363.81 million during the quarter, compared to analyst estimates of $355.06 million. During the same period in the prior year, the business posted ($0.02) earnings per share. LifeStance Health Group's revenue for the quarter was up 16.3% on a year-over-year basis.  As a group, equities analysts predict that  LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year. </p><h2>About LifeStance Health Group</h2> (Free Report)<p>LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than LifeStance Health Group</li><li>What Do S&amp;P 500 Stocks Tell Investors About the Market? </li><li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li><li>The 3 Best Blue-Chip Stocks to Buy Now</li><li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li><li>What Are Earnings Reports?</li><li>MarketBeat Week in Review – 12/1 - 12/5</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZTVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in LifeStance Health Group Right Now?</h2><p>Before you consider LifeStance Health Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.</p><p>While LifeStance Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LFST

<p>Brown Advisory Inc. reduced its stake in LifeStance Health Group by 10.5% in Q2, selling 611,977 shares. Analysts have mixed ratings on LFST, with a moderate buy consensus and a target price of $9.00. Insider Lisa K. Miller sold 57,240 shares. LFST reported Q3 earnings of $0.02 per share, beating estimates, with revenue up 16.3% year-over-year.</p>

Brown Advisory Inc. Sells 611,977 Shares of LifeStance Health Group, Inc. $LFST